Xavier HÃ©buterne

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10555921/publications.pdf

Version: 2024-02-01

93	8,759	57758 44	43889 91
papers	citations	h-index	g-index

102	102	102	11703
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet, The, 2009, 374, 1617-1625.	13.7	996
2	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet, The, 2017, 390, 2779-2789.	13.7	633
3	Prevalence of Malnutrition and Current Use of Nutrition Support in Patients With Cancer. Journal of Parenteral and Enteral Nutrition, 2014, 38, 196-204.	2.6	537
4	A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nature Genetics, 2011, 43, 242-245.	21.4	523
5	ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clinical Nutrition, 2017, 36, 321-347.	5.0	457
6	ESPEN Guidelines on Parenteral Nutrition: Home Parenteral Nutrition (HPN) in adult patients. Clinical Nutrition, 2009, 28, 467-479.	5.0	365
7	Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the) Tj ETQq1 1 0.784314 rgBT /Overlock The, 2017, 389, 266-275.	13.7	353
8	Malnutrition is an independent factor associated with nosocomial infections. British Journal of Nutrition, 2004, 92, 105-111.	2.3	295
9	Long-term follow-up of patients on home parenteral nutrition in Europe: implications for intestinal transplantation. Gut, 2011, 60, 17-25.	12.1	246
10	Omega-3 Free Fatty Acids for the Maintenance of Remission in Crohn Disease. JAMA - Journal of the American Medical Association, 2008, 299, 1690.	7.4	236
11	ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease. Clinical Nutrition, 2020, 39, 632-653.	5.0	211
12	Nutritional deficiencies in patients with CrohnÊ¼s disease in remission. Inflammatory Bowel Diseases, 2006, 12, 185-191.	1.9	208
13	Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut, 2011, 60, 198-203.	12.1	160
14	Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 135-144.	13.7	157
15	Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut, 2013, 62, 201-208.	12.1	147
16	Candidates for Intestinal Transplantation: A Multicenter Survey in Europe. American Journal of Gastroenterology, 2006, 101, 1633-1643.	0.4	129
17	Deep Remission at 1 Year Prevents Progression of Early Crohnâ€™s Disease. Gastroenterology, 2020, 159, 139-147.	1.3	126
18	ESPEN Guidelines on Parenteral Nutrition: Gastroenterology. Clinical Nutrition, 2009, 28, 415-427.	5.0	119

#	Article	IF	Citations
19	Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 423-431.e1.	4.4	117
20	Sarcopenia is prevalent in patients with CrohnÊ¼s disease in clinical remission. Inflammatory Bowel Diseases, 2008, 14, 1562-1568.	1.9	116
21	Clinical practice guidelines from the French health high authority: Nutritional support strategy in protein-energy malnutrition in the elderly. Clinical Nutrition, 2011, 30, 312-319.	5.0	114
22	Nutritional support during oncologic treatment of patients with gastrointestinal cancer: Who could benefit?. Cancer Treatment Reviews, 2008, 34, 568-575.	7.7	106
23	Survival of Patients Identified as Candidates for Intestinal Transplantation: A 3-Year Prospective Follow-Up. Gastroenterology, 2008, 135, 61-71.	1.3	105
24	Bone marrow Th17 TNFÎ± cells induce osteoclast differentiation, and link bone destruction to IBD. Gut, 2015, 64, 1072-1081.	12.1	102
25	Genetic and Pharmacological Inactivation of the Purinergic P2RX7 Receptor Dampens Inflammation but Increases Tumor Incidence in a Mouse Model of Colitis-Associated Cancer. Cancer Research, 2015, 75, 835-845.	0.9	96
26	Gut changes attributed to ageing: effects on intestinal microflora. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 49-54.	2.5	94
27	Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2011, 5, 484-498.	1.3	93
28	Effects of total enteral nutrition supplemented with a multi-fibre mix on faecal short-chain fatty acids and microbiota. Clinical Nutrition, 2006, 25, 82-90.	5.0	90
29	Effects ofSaccharomyces boulardiion fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World Journal of Gastroenterology, 2005, 11, 6165.	3.3	88
30	Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohnâ€™s disease: report of the OPERA study. Gut, 2018, 67, 1824-1835.	12.1	87
31	Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. Clinical Gastroenterology and Hepatology, 2015, 13, 1770-1775.	4.4	84
32	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 892-899.e2.	4.4	80
33	Muscle Performance in Patients With CrohnÊ¼s Disease in Clinical Remission. Inflammatory Bowel Diseases, 2005, 11, 296-303.	1.9	75
34	Development of the IBD Disk. Inflammatory Bowel Diseases, 2017, 23, 333-340.	1.9	72
35	Acute Renutrition by Cyclic Enteral Nutrition in Elderly and Younger Patients. JAMA - Journal of the American Medical Association, 1995, 273, 638.	7.4	71
36	Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physiciansâ€"Results of the NutriCancer2012 Study. Journal of Parenteral and Enteral Nutrition, 2018, 42, 255-260.	2.6	71

#	Article	IF	Citations
37	Energy metabolism and substrate oxidation in patients with Crohnâ€™s Disease. Nutrition, 2000, 16, 173-178.	2.4	69
38	Subversion of Autophagy in Adherent Invasive Escherichia coli-Infected Neutrophils Induces Inflammation and Cell Death. PLoS ONE, 2012, 7, e51727.	2.5	58
39	Lack of adaptation to severe malnutrition in elderly patients. Clinical Nutrition, 2002, 21, 499-504.	5.0	57
40	Amplification loop of the inflammatory process is induced by P2X₇R activation in intestinal epithelial cells in response to neutrophil transepithelial migration. American Journal of Physiology - Renal Physiology, 2010, 299, G32-G42.	3.4	57
41	Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. American Journal of Physiology - Renal Physiology, 2009, 296, G1332-G1343.	3.4	54
42	Clinical nutrition guidelines of the French Speaking Society of Clinical Nutrition and Metabolism (SFNEP): Summary of recommendations for adults undergoing non-surgical anticancer treatment. Digestive and Liver Disease, 2014, 46, 667-674.	0.9	54
43	Outcome of Patients Treated with Home Enteral Nutrition. Journal of Parenteral and Enteral Nutrition, 2001, 25, 203-209.	2.6	48
44	Use of Nutritional Scores to Predict Clinical Outcomes in Chronic Diseases. Nutrition Reviews, 2000, 58, 31-38.	5.8	48
45	Monitoring of patients on home parenteral nutrition (HPN) in Europe: A questionnaire based study on monitoring practice in 42 centres. Clinical Nutrition, 2006, 25, 693-700.	5.0	41
46	Low Risk of Irritable Bowel Syndrome afterClostridium difficileInfection. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 727-731.	1.7	40
47	Impact of restrictive diets on the risk of undernutrition in a free-living elderly population. Clinical Nutrition, 2012, 31, 69-73.	5.0	39
48	Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 1063-1075.	8.1	35
49	Body composition, anthropometrics, energy expenditure, systemic inflammation, in premenopausal women 1Âyear after laparoscopic Roux-en-Y gastric bypass. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 500-507.	2.4	34
50	NutriCancer: A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer. Journal of Geriatric Oncology, 2018, 9, 74-80.	1.0	32
51	Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial. Gastroenterology, 2021, 160, 2595-2598.e3.	1.3	32
52	Effects of age, malnutrition and refeeding on the expression and secretion of ghrelin. Clinical Nutrition, 2008, 27, 724-731.	5.0	29
53	Treatment algorithms in Crohn's â€“ Up, down or something else?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 473-483.	2.4	29
54	Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterology Journal, 2021, 9, 552-560.	3.8	28

#	Article	IF	Citations
55	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohnâ€™s Disease: A Post Hoc Analysis From the CALM Study. Inflammatory Bowel Diseases, 2020, 26, 1562-1571.	1.9	27
56	Effect of steroids on energy expenditure and substrate oxidation in women with crohn's disease. American Journal of Gastroenterology, 2002, 97, 2843-2849.	0.4	26
57	Feeding the patients with upper gastrointestinal bleeding. Current Opinion in Clinical Nutrition and Metabolic Care, 2011, 14, 197-201.	2.5	26
58	Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study. Journal of Crohn's and Colitis, 2014, 8, 161-165.	1.3	24
59	Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. Inflammatory Bowel Diseases, 2016, 22, 1362-1369.	1.9	24
60	Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. Journal of Crohn's and Colitis, 2021, 15, 938-949.	1.3	23
61	Colon capsule endoscopy to screen for colorectal neoplasia inÂthose with family histories of colorectal cancer. Gastrointestinal Endoscopy, 2018, 87, 695-704.	1.0	22
62	Role of adherent and invasiveEscherichia coliin Crohnâ€™s disease: lessons from the postoperative recurrence model. Gut, 2023, 72, 39-48.	12.1	22
63	French national consensus clinical guidelines for the management of Crohnâ€™s disease. Digestive and Liver Disease, 2017, 49, 368-377.	0.9	19
64	Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2022, 16, 1269-1280.	1.3	15
65	French national consensus clinical guidelines for the management of ulcerative colitis. Digestive and Liver Disease, 2016, 48, 726-733.	0.9	14
66	Nutrition and physical activity: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC, SFP-APA,) Tj ETQq1 1 0 rgBT /Overlock 1	1.0	12
67	Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease. Digestive and Liver Disease, 2020, 52, 740-744.	0.9	12
68	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. Journal of Crohn's and Colitis, 2020, 14, 896-903.	1.3	12
69	The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 766-773.	1.3	11
70	Faster and less invasive tools to identify patients with ileal colonization by adherentâ€invasive E. coli in Crohn's disease. United European Gastroenterology Journal, 2021, 9, 1007-1018.	3.8	11
71	Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 832-840.	2.8	11
72	Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohnâ€™s Disease: The OPERA II Study. Inflammatory Bowel Diseases, 2022, 28, 1034-1044.	1.9	10

#	Article	IF	Citations
73	Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Digestive and Liver Disease, 2022, 54, 309-315.	0.9	10
74	Endoscopic Mucosal Improvement in Patients with Active CrohnÊ¼s Disease Treated with Certolizumab Pegol. American Journal of Gastroenterology, 2008, 103, S432.	0.4	8
75	Nutritional support of the elderly cancer patient: Long-term nutritional support. Nutrition, 2015, 31, 617-618.	2.4	7
76	Review article: randomised controlled trials in inflammatory bowel diseaseâ€"common challenges and potential solutions. Alimentary Pharmacology and Therapeutics, 2022, 55, 658-669.	3.7	7
77	A telephone-linked computer system for home enteral nutrition. Journal of Telemedicine and Telecare, 2010, 16, 363-367.	2.7	5
78	Nutrition et cancerÂ: pourquoi intervenir avant 5Â% de perte de poidsÂ?. Nutrition Clinique Et Metabolisme, 2015, 29, 126-131.	0.5	5
79	Endoscopic balloon dilation of colorectal strictures complicating Crohnâ€™s disease: a multicenter study. Clinics and Research in Hepatology and Gastroenterology, 2020, 45, 101561.	1.5	4
80	Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. Digestive and Liver Disease, 2020, 52, 704-720.	0.9	4
81	Prise en charge nutritionnelle Ã domicile des malades cancÃ©reux. Nutrition Clinique Et Metabolisme, 2001, 15, 335-342.	0.5	3
82	The management of emergency hospital visits for inflammatory bowel diseases: A French national expert consensus report. Digestive and Liver Disease, 2020, 52, 420-426.	0.9	3
83	Quand faut-il poser une gastrostomie percutanÃ©e endoscopique chez un sujet Ã¢gÃ©Â?. Nutrition Clinique Et Metabolisme, 2005, 19, 126-130.	0.5	2
84	MÃ©tabolisme et apports en acides aminÃ©s chez le sujet Ã¢gÃ©. Nutrition Clinique Et Metabolisme, 2008, 22, 183-188.	0.5	2
85	Methaemoglobinaemia and renal failure following mesalazine for treatment of inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 900-901.	1.3	2
86	Conduite Ã tenir pratique pour lâ€™exploration dâ€™une malabsorption, dâ€™une maldigestion, et dâ€™une entÃ©ropathie exsudative. Nutrition Clinique Et Metabolisme, 2016, 30, 98-104.	0.5	2
87	Tackling needs for clinical nutrition at local level: The Nutriâ€™Action campaign in France. Clinical Nutrition Supplements, 2007, 2, 33-37.	0.0	1
88	Nutrition anti-inflammatoire et MICIÂ: que dire Ã nos patientsÂ?. Nutrition Clinique Et Metabolisme, 2019, 33, 126-130.	0.5	1
89	Effectiveness and tolerance of an oral nutritional supplement highly concentrated in protein and energy in elderly subjects at risk of malnutrition. Nutrition Clinique Et Metabolisme, 2020, 34, 156-160.	0.5	1
90	Mucosal p-STAT1/3 correlates with histologic disease activity in Crohnâ€™s disease and is responsive to filgotinib. Tissue Barriers, 2023, 11, .	3.2	1

#	Article	IF	Citations
91	P081â€ƒRapid Symptomatic Remission in Patients With Ulcerative Colitis Treated With the Anti-MAdCAM-1 Antibody Ontamalimab: Results From TURANDOT and TURANDOT II. American Journal of Gastroenterology, 2019, 114, S21-S22.	0.4	0
92	Motivation to pursue anti-TNFÎ± treatment in patients with Crohn's disease â€“ the SPACE motivation study. Digestive and Liver Disease, 2020, 52, 995-1001.	0.9	0
93	Prevalence of malnutrition in PS 0-1 cancer patients: Results of the NutriCancer2 one-day national survey in 2,197 cancer patients.. Journal of Clinical Oncology, 2015, 33, 1587-1587.	1.6	0